Share

May 19, 2020; 94 (20) Article

Retinal pathology occurs in stiff-person syndrome

Jeffrey Lambe, Alissa Rothman, Jerry Prince, Shiv Saidha, Peter A. Calabresi, Scott D. Newsome
First published January 10, 2020, DOI: https://doi.org/10.1212/WNL.0000000000008943
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
107

Share

Article Information

vol. 94 no. 20 e2126-e2131
DOI: 
https://doi.org/10.1212/WNL.0000000000008943
PubMed: 
31924684
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 14, 2019
  • Accepted in final form November 25, 2019
  • First Published January 10, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Jeffrey Lambe, MBBCh, MRCPI,
    2. Alissa Rothman, BS,
    3. Jerry Prince, PhD,
    4. Shiv Saidha, MBBCh, MD, MRCPI,
    5. Peter A. Calabresi, MD and
    6. Scott D. Newsome, DO
  1. Jeffrey Lambe, MBBCh, MRCPI,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Alissa Rothman, BS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jerry Prince, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) IFlyTek Health, travel funds to present a talk at IFlyTek's annual meeting. (2) University of California Irvine, travel funds to give a presentation. (3) Cornell University, travel funds to give a presentation. (4) University of Wisconsin Madison, travel funds to give a presentation. (5) Massachusetts Institute of Technology, travel funds to give a presentation. (6) University of Waterloo, travel funds to give a presentation.

    Editorial Boards:

    1. (1) Medical Image Analysis, Editorial Board Member, 2003-present

    Patents:

    1. (3) 2D B-mode ultrasound pose recovery via surgical fiducial segmentation and tracking (4) Pulse sequence-based intensity normalization and contrast synthesis for magnetic resonance imaging (5) A fast deep learning based topology guaranteed segmentation method for retina OCT images (6) A Deep Learning Based Anti-aliasing Self Super-resolution Algorithm for Magnetic Resonance Images

    Publishing Royalties:

    1. (1) Medical Imaging Signals and Systems, Pearson Prentice Hall, 2006 (2) Medical Imaging Signals and Systems (2e), Pearson Prentice Hall, 2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Sonavex, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Ongoing (J.L. Prince) (1) 1 R01 DC014717 (PI: J.L. Prince) 08/07/15 – 07/31/20 Source: NIH/NIDCD Title: Tongue muscle function after cancer surgery using 4D MRI, DTI, and MR tagging To develop imaging and image processing methods in order to evaluate speech pathologies and strategies in speech after partial glossectomy. Role: PI (2) 2 R56 NS055951 (PI: P.V. Bayly) 09/01/2018 – 08/31/2020 Source: NIH/NINDS Title: In Vivo Measurement of Brain Biomechanics To measure brain motion and biomechanical properties in mild accelerations and to predict the results of larger impacts using finite element modeling. Role: Co-Investigator and Site PI (3) 1 U01 NS112120 (PI: P.V. Bayly) 09/15/2019 – 07/31/2024 Source: NIH/NINDS Title: MRI Measurement of the Mechanical Vulnerability of the Brain To deliver comprehensive measurements of 3D deformation of the human brain, in males and females of different ages, caused by skull motions of different types, directions, and frequency content. Role: Co-Investigator and Site PI (4) 1 R01 NS082347 (PI: P.A. Calabresi) 04/01/2018 – 01/31/2023 Source: NIH/NINDS Title: Imaging neurodegeneration in MS This grant will develop a multi-faceted approach to monitor people with MS with imaging and to predict disease severity in order to guide individualized disease modifying therapy. (5) N/A (PI: E. Mowry) 01/02/2018-12/31/2022 Source: PCORI Title: A Pragmatic Trial to Evaluate the Intermediate-Term Effects of Early, Aggressive versus Escalation Therapy in People with Multiple Sclerosis This grant will recruit newly diagnosed people with MS, put them on either aggressive or escalation therapy, and then track them over 4-5 years to determine the impact of the different initial therapies. Role: Co-Investigator and Director of MRI Analysis Core (6) MS180179 (PI: S. Saidha) 09/01/2019 – 08/31/2022 Source: CDMRP Title: Inner and outer nuclear layer atrophy of the retina a novel and distinguishing biomarkers for defining and tracking progressive multiple sclerosis The primary objective is to confirm that changes in the thickness of particular layers within the retina (the inner and outer nuclear layers) of people with multiple sclerosis (MS) correlate with disease progression, specifically in progressive MS(PMS). Role: Co-Investigator Recently Completed (7) 1 R01 EY024655-01 (PI: J.L. Prince) 08/01/2014-06/30/2019 Source: NIH/NEI Title: 3D segmentation and registration of macular SD-OCT for application in MS. The research will develop segmentation and registration methods for spectral domain optical coherence tomography for application in multiple sclerosis. Methods based on random forests and multi-object geometric deformable models will be developed. (8) 1 R21 NS096497 (PI: J.L. Prince) 04/01/16 – 03/31/19 Source: NIH/NINDS Title: Ventricle segmentation and labeling to characterize normal pressure hydrocephalus To develop image processing methods to segment the ventricles in normal pressure hydrocephalus

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (4) RG-1507-05243 (PI: D.L. Pham) 04/01/2016-03/31/2020 Source: National MS Society This study will develop algorithms and software tools to effectively detect and characterize MS lesions and segment brain structure to help explore and discover imaging biomarkers to MS disease monitoring. Role: Co-Investigator and Site PI

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Sonavex, Inc.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Method of Employing Angle Images for Measuring Object Motion in Tagged Magnetic Resonance Imaging, Myocardial Solutions, Inc. (2) Cardiac Motion Tracking Using CINE Harmonic Phase (HARP) Magnetic Resonance Imaging, Myocardial Solutions, Inc. (3) Ultrafast Motion Imaging Using Harmonic Phase MRI (HARP-MRI), Myocardial Solutions, Inc. (4) Application for the Mark "HARP", Myocardial Solutions, Inc. (5) Imaging Tissue Deformation Using Strain Encoded (SENC) Magnetic Resonance Imaging (MRI), Myocardial Solutions, Inc. (6) zHARP: Three-Dimensional Magnetic Resonance Motion Estimation of a Single Image Plane, Myocardial Solutions, Inc. (7) Robotic 5D Ultrasound System, Acoustic MedSystems, Inc. (8) Robotic 5D Ultrasound System, Intuitive Surgical Inc. (9) Method for Localizing Radiation Implants from Limited X-ray Data, Acoustic MedSystems, Inc. Stock/Stock Options, Medical Equipment & Materials: (1) Sonavex, Inc., 2015-present

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Shiv Saidha, MBBCh, MD, MRCPI,
    5. Scientific Advisory Boards:

    1. Dr. Saidha has served on scientific advisory boards for Biogen, Celgene, EMD Serono, Genentech, and Genzyme Corp.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I am a member of the editorial board of Multiple Sclerosis Journal.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting fees from Medical Logix for the development of CME programs in neurology, and has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Saidha is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen, and is also the site investigator of a trial sponsored by MedDay Pharmaceuticals.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr. Saidha receives research funding from the National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Peter A. Calabresi, MD and
    6. Scientific Advisory Boards:

    1. 1. DiSARM Therapeutics 2. Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. NMSS (travel only) 2. Myelin Repair Foundation (honorarium)

    Editorial Boards:

    1. Neurology Editorial Board 2007 to 2017 Journal of Clinical Investigation Associate Editor-present Multiple Sclerosis Journal Editorial Board-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. Optical Coherence Tomography in Neurological Diseases (book) Royalties for being co-editor received from Cambridge Press.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. DiSARM Therapeuuutics 2. Biogen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. We utilize OCT in the clinic and bill for patients not enrolled in research studies. I have been a co-author on papers outlining guidelines for use of OCT.

    Research Support, Commercial Entities:

    1. 1 Biogen-IDEC 2. MedImmune 3. Annexon

    Research Support, Government Entities:

    1. NIH, NINDS NS R-37 041435 PI 2013-2020 PI NIH, NINDS R-01 NS082347-01 2018-2023 PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NMSS Collaborative Center Grant 2012-2017 NMSS Clinical Fellowship grant to JHU Nancy Davis Race to Erase MS Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Scott D. Newsome, DO
    7. Scientific Advisory Boards:

    1. Biogen Idec, scientific advisory board Genentech, scientific advisory board EMD Serono, scientific advisory board Celgene, scientific advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Idec; research support payed directly to my institution and not relevant to the submitted manuscript Novartis; research support payed directly to my institution and not relevant to the submitted manuscript Genentech; research support payed directly to my institution and not relevant to the submitted manuscript

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society Department of Defense Patient Centered Outcomes Research Institute

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neurology (J.L., A.R., S.S., P.A.C., S.D.N.) and Electrical and Computer Engineering (J.P.), Johns Hopkins University School of Medicine, Baltimore, MD.
  1. Correspondence
    Dr. Newsome snewsom2{at}jhmi.edu
View Full Text

Article usage

Article usage: January 2020 to December 2021

AbstractFullPdfSource
Jan 2020424027Highwire
Feb 20205705Highwire
Mar 20209404Highwire
Apr 20205103Highwire
May 20204384933Highwire
Jun 202010889Highwire
Jul 20207923Highwire
Aug 20204412Highwire
Sep 20206942Highwire
Oct 20205732Highwire
Nov 20202831Highwire
Dec 20207810Highwire
Jan 20216621Highwire
Feb 20215711Highwire
Mar 20214351Highwire
Apr 20213101Highwire
May 20212310Highwire
Jun 20213722Highwire
Jul 20212000Highwire
Aug 20213022Highwire
Sep 20214314Highwire
Oct 20213001Highwire
Nov 20211832Highwire
Dec 20214301Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me